ASPET

OCTOBER 12, 2023

To maintain cadence with looming threats in a prolonged field care environment, the broader medical countermeasure (MCM) enterprise must adopt new strategies for CBRN-addressing drug development. CBRN MCMs).

Therapies 100

Therapies Licensing Licensing FDA Approval 100

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Therapies Pharmaceutical Companies 52

The Pharma Data

JUNE 16, 2025

This collaboration marks a significant step forward in global oncology drug development. Fosun Pharma is granted an exclusive license to develop, manufacture, and commercialize TEV-56278 in Chinese mainland, Hong Kong Special Administrative Region (SAR), Macau SAR, Taiwan, and select Southeast Asian countries.

Therapies 40

Therapies Licensing Licensing Treatment 40

The Pharma Data

NOVEMBER 30, 2020

Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries.

Licensing 52

Licensing Licensing Production Drug Development 52

Drug Target Review

APRIL 14, 2025

The antibiotic market has long faced significant barriers to innovation, with structural issues that make it difficult for new antibiotics to gain traction. As the demand for novel antibiotics remains limited due to the preference for cheaper generics, the market has struggled to incentivise much-needed breakthroughs.

Therapies 52

Therapies Marketing Drug Development Treatment 52

Drug Patent Watch

JANUARY 21, 2021

This article was first published by Elinevan Overbeeke, Sissel Michelsen, Mondher Toumi, Hilde Stevens, Mark Trusheim, Isabelle Huys, and StevenSimoens in Drug Discovery Today under a Creative Commons License. Highlights….

Therapies 52

Therapies Marketing Licensing Licensing 52

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in January 2022.

Licensing 52

Licensing Licensing Vaccine FDA 52

The Pharma Data

JANUARY 6, 2021

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. LOS ANGELES , Jan. 7, 2021 /PRNewswire/ — ImaginAb Inc. , No other terms were disclosed.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

Drug Channels

MARCH 15, 2022

Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Examines Consolidation and Vertical Integration of U.S. Prescription Market (press release) We’re offering special discounted pricing if you order before March 28, 2022.

Pharmacy 98

Pharmacy Specialty Pharmacies Licensing Licensing 98

Drug Target Review

NOVEMBER 25, 2024

Her journey in drug R&D and business development has been marked by significant achievements, including leading groundbreaking efforts to treat neglected cancers and breaking barriers for women in the biotech industry. I went on to complete my MBA and PhD at The Institute of Cancer Research (ICR) in drug development.

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

Drug Channels

FEBRUARY 21, 2023

On March 14, 2023, Drug Channels Institute will release The 2023 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. we highlight potential implications of the IRA for the drug channel. If you have any questions before purchasing a license to the report, please email me. In Subsection 12.5.1.,

Pharmacy 97

Pharmacy Specialty Pharmacies Licensing Licensing 97

Drug Patent Watch

JANUARY 14, 2025

From mergers and acquisitions to licensing agreements and pricing discussions, these complex interactions demand a unique blend of scientific knowledge, business acumen, and interpersonal skills. These agreements tie a drug’s price to its real-world performance, aligning the interests of manufacturers, payers, and patients.

Pharmaceuticals 53

Pharmaceuticals Compliance Licensing Licensing 53

Drug Channels

OCTOBER 5, 2021

Click here to download a free report overview (including a summary of industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study: Biosimilars Are Delivering Higher Profits for Drug Distributors (press release) We’re offering special discounted pricing if you order before October 15, 2021!

Pharmaceuticals 75

Pharmaceuticals Biosimilars Licensing Licensing 75

The Pharma Data

MAY 7, 2021

BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States (together with Pfizer), United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

DECEMBER 20, 2020

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Licensing 40

Licensing Licensing Pharmaceuticals Pharmaceutical Companies 40

The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8 Juyou Bio-Technology Co.,

Licensing 40

Licensing Licensing Production Engineering 40

Drug Target Review

APRIL 23, 2024

Drug discovery is a complex process, where millions of compounds are investigated throughout the initial hit identification, hit-to-lead, and lead optimisation stages. The process of drug discovery is lengthy, and it can take 2-5 years on average to reach the preclinical phase. percent, to reach $8.77 billion by 2031. billion by 2031.

Licensing 100

Licensing Licensing Drugs Drug Development 100

DrugBank

OCTOBER 4, 2024

This involves assessing the strength and breadth of patents, evaluating the potential for future patent challenges, and analyzing the value derived from licensing agreements and royalty streams. The Evolving Regulatory System Regulatory frameworks play a pivotal role in shaping the pharmaceutical M&A landscape.

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

The Pharma Data

AUGUST 19, 2021

today announced that the company’s Marketing Authorization Application (MAA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, has been fully validated and is now under evaluation with the European Medicines Agency (EMA). In June 2021, Gilead submitted a New Drug Application (NDA) for lenacapavir seeking U.S.

Marketing 52

Marketing Treatment FDA FDA Approval 52

Drug Channels

APRIL 15, 2025

Whether you're building trust with customers, launching new products, or guiding internal teams, understanding the economic forces that shape drug distribution, reimbursement, and pricing is essential. We also offer licenses to our secure hosted learning environmentno internal setup required! Visit our eLearning page to get started.

Specialty Pharmacies 52

Specialty Pharmacies Pharmaceuticals Pharmacy Licensing 52

Drug Channels

OCTOBER 11, 2022

Click here to download a free report overview (including a summary of industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study: U.S. We also update sections that were introduced in recent editions, such as our estimates of wholesalers' profits from provider-administered biosimilar drugs.

Pharmaceuticals 74

Pharmaceuticals Biosimilars Licensing Licensing 74

Policy Prescription

OCTOBER 3, 2023

Salant’s paper supports personal drug importation and legalizing the importation of prescription drugs for commercial use so that wholesale pharmacies, including companies like Amazon and Costco, could tap into the parallel importation markets of other countries. First, drug prices in the U.S. He points to “a mere 1.5%

Pharmacy 84

Pharmacy International Government FDA Approval 84

The Pharma Data

AUGUST 17, 2020

Food and Drug Administration clearance in May 2020 for its investigational new drug application to develop DF6002. DF6002 is a monovalent IL-12 immunoglobulin Fc fusion protein proposed to achieve strong anti-tumor efficacy by establishing an inflammatory tumor microenvironment necessary for productive anti-tumor responses.

Licensing 52

Licensing Licensing Production Clinical Trials 52

Predictive Oncology

MARCH 21, 2023

Pamela Bush of Predictive Oncology discuss the potential impact of their collaboration and how it can advance cancer drug development. The post Proactive interviews Predictive Oncology about partnering with Cancer Research Horizons to leverage AI for new cancer drugs appeared first on Predictive Oncology.

Research 52

Research Licensing Licensing Drugs 52

LifeSciVC

APRIL 24, 2024

Is a novel target at the inflection point where enough evidence is available to suggest it may prove to be a compelling drug? Directionality and Druggability: Does the proposed “direction” of insult and therapeutic intervention make sense, and can we drug our novel target with a compelling modality?

Production 131

Production Small Molecule Regulations Trials 131

DS in Pharmatics

APRIL 4, 2025

Navigating the regulatory pathways for drug approvals in the U.S. can be complex, especially when determining whether a Biologics License Application (BLA) or a New Drug Application (NDA) is the appropriate route. While both serve as formal requests for market approval from the FDA, they apply to different types of []

Licensing 52

Licensing Licensing FDA Marketing 52

New Drug Approvals

JUNE 11, 2025

2] Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. [4] 4] This came after the drug had been rejected by the Food and Drug Administration (FDA) three times over two decades due to insufficient evidence of effectiveness. [5] Food and Drug Administration.

FDA 62

FDA FDA Approval Treatment Clinical Trials 62

The Pharma Data

MARCH 30, 2021

These targeted drugs bind to markers or proteins over-expressed by certain tumors, or tumor-associated tissue, such as stroma. There can be no guarantee that the FAP targeting agents, including FAPI-46 and FAPI-74, will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time.

Therapies 52

Therapies Licensing Licensing Protein Expression 52

The Pharma Data

AUGUST 13, 2020

The drug was discovered by SK Biopharmaceuticals and SK life science and has been approved by the FDA to treat partial-onset seizures in adults. SK Biopharmaceuticals entered an exclusive licensing agreement with Arvelle to develop the treatment in Europe. This scheme also helps get treatments for those in medical need.

Drugs 52

Drugs Licensing Licensing Treatment 52

Drug Target Review

AUGUST 9, 2024

What is drug formulation? Drug formulation is the process of designing and producing a final medicinal product from an active pharmaceutical ingredient (API). 1 The goal is to create a dosage form that delivers the drug effectively to the intended site of action with optimal patient benefit and a good commercial value.

Science 59

Science Drugs Compliance Drug Development 59

DrugBank

MARCH 22, 2024

There are many obstacles that you have to overcome on the road to success in early-stage drug discovery and drug repurposing research. Their focus can be on anything from drug targets, indications, drug product details, clinical trial details, or drug categorization.

Licensing 98

Licensing Licensing Research Pharmaceutical Companies 98

The Premier Consulting Blog

NOVEMBER 20, 2024

This process can be initiated during the review period of the biologics license application (BLA) or new drug application (NDA) prior to approval. ii When appropriately applied, concurrent validation provides a powerful tool to address impractical limitations of bringing new drugs and biologics to market.

Small Molecule 52

Small Molecule Drugs FDA Production 52

Predictive Oncology

MARCH 17, 2023

Cancer Research Horizons to incorporate PEDAL into future drug discovery processes to enable drug development on a global scale 11 marketed drugs 2nd largest oncology out-licensor globally 150+ active licenses 160+ new drugs into early-phase clinical trials $647 million revenue from royalties & IP $2.8

Research 52

Research Clinical Trials Licensing Licensing 52

FDA Law Blog: Biosimilars

SEPTEMBER 18, 2024

By Riëtte van Laack — The dietary supplement exclusionary clause is, as its name suggests, a clause in the Federal Food, Drug, and Cosmetic Act (FDC Act) definition of dietary supplement. That clause excludes those ingredients that were first marketed as drug ingredients.

Production 59

Production FDA Licensing Licensing 59

Drug Channels

MARCH 18, 2025

I am pleased to announce that Drug Channels Institutes new 2025 Economic Report on U.S. Download a free 30-page report overview including key industry trends, What's New in this edition, the Table of Contents, and a List of Exhibits Read the press release: HMP Globals Drug Channels Institute Releases 2025 Economic Report on U.S.

Pharmacy 52

Pharmacy Specialty Pharmacies Licensing Licensing 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). . TOKYO and CAMBRIDGE, England , Dec. Vlad Coric , M.D.,

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

Drug Target Review

SEPTEMBER 19, 2024

Could you give us an overview of IRLAB’s current drug development pipeline? The pipeline currently includes five drug candidates, all of which have the potential to revolutionise the treatment of PD. Based on the positive efficacy and safety data generated in Phase I and II, the plan is to initiate a Phase III programme for mesdopetam.

Disease 52

Disease Drugs Treatment Drug Development 52